HC
RXRX icon

Hurley Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Hurley Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12K Hold
850
– – ﹤0.01% 515
2026
Q1 		$2.61K Hold
850
– – ﹤0.01% 546
2025
Q4 		$3.48K Buy
+850
New +$4.21K ﹤0.01% 477

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hurley Capital's RXRX Position: Q2 2026 in Review

Hurley Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 850 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #515.

Hurley Capital first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.48K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Hurley Capital held 850 shares of Recursion Pharmaceuticals worth $3.12K as of Q2 2026.
  • Hurley Capital left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #515 holding.
  • Hurley Capital first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Hurley Capital's Recursion Pharmaceuticals position peaked at $3.48K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.